MENU
PTGX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Protagonist Therapeutics (PTGX) Earnings Date & Reports

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

PTGX is expected to report earnings to fall 108.41% to -25 cents per share on March 02

Protagonist Therapeutics PTGX Stock Earnings Reports
Q4'26
Est.
$-0.26
Q3'26
Beat
by $0.49
Q2'26
Beat
by $0.16
Q1'26
Beat
by $0.54
Q4'25
Missed
by $0.35
The last earnings report on November 05 showed earnings per share of $3.07, beating the estimate of $2.58. With 220.81K shares outstanding, the current market capitalization sits at 8.54B.
A.I.Advisor
Nov 05, 2026

Protagonist Therapeutics (PTGX) Third Quarter 2026 Earnings Recap: Milestone Payments Take Center Stage

Key Takeaways

  • Protagonist Therapeutics reported total license and collaboration revenue of $274.4 million for the third quarter of 2026, up from just $4.7 million in the same period a year earlier.
  • Net income reached $220.0 million, or $3.07 per diluted share, compared with a net loss of $39.3 million, or $0.62 per share, in the prior-year quarter.
  • The top line was driven by the proportional recognition of $266.6 million tied to $275.0 million earned from partner Takeda, including a $75 million milestone triggered by the FDA approval of MIMRYLO and a further $200 million opt-out fee.
  • The company ended the quarter with $834.6 million in cash, cash equivalents, and marketable securities, up from $646.0 million at the end of 2025.
  • Reported results surpassed analyst expectations, with adjusted diluted EPS of $3.07 beating a consensus estimate of $2.58.
  • For more details, explore the latest Major News, Today's Price Move, Price Targets, and Forecast pages for the PTGX ticker.
  • Discover how automation is reshaping the market by exploring Trending AI Robots.

Earnings Context and Why It Matters

Protagonist Therapeutics has transformed from a pre-revenue, research-stage biotech into a company with two FDA-approved medicines generating royalties and milestone income through global partnerships with Johnson & Johnson and Takeda. This quarter offered investors the first clear look at how the August 2026 FDA approval of MIMRYLO (rusfertide), its polycythemia vera treatment partnered with Takeda, flows through the income statement alongside ICOTYDE (icotrokinra), its psoriasis therapy licensed to Johnson & Johnson. The results matter because they test whether the company's partnership-driven model can convert regulatory milestones into durable, high-margin revenue while it simultaneously funds a deepening internal pipeline.

Reported Results

For the third quarter of 2026, Protagonist Therapeutics reported license and collaboration revenue of $274.4 million, compared with $4.7 million in the same period of 2025. This figure was driven primarily by the proportional recognition of $266.6 million related to $275.0 million earned from Takeda during the quarter. Those payments, received in cash in October 2026, consisted of a further $200 million opt-out fee and a separate $75 million milestone triggered by the FDA approval of MIMRYLO. The remaining roughly $7.8 million came from ongoing development services under the Takeda collaboration agreement and other revenue.

Net income for the quarter was $220.0 million, or $3.32 per basic share and $3.07 per diluted share, versus a net loss of $39.3 million, or $0.62 per share, a year earlier. For the nine months ended September 30, 2026, revenue totaled $544.3 million and net income reached $386.6 million, or $5.43 per diluted share.

Operating expenses rose modestly. Research and development (R&D) expense increased to $41.3 million from $40.0 million, while general and administrative (G&A) expense rose to $13.7 million from $11.1 million. Management guided that R&D spending is expected to increase through the remainder of the year as it advances PN-881 into a comprehensive Phase 2 psoriasis program and prepares other candidates for clinical development. On an adjusted basis, earnings of $3.07 per share surpassed a consensus estimate of $2.58, while reported revenue also came in slightly ahead of expectations.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, saving time while surfacing signals that might otherwise be missed. Investors tracking names like Protagonist Therapeutics can use the AI Screener to compare peers, monitor momentum, and spot new opportunities across the broader biotechnology and healthcare landscape.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around Protagonist Therapeutics was broadly positive, supported by two commercial-stage products and a strong cash position. Analysts covering the stock maintained favorable ratings, with the company's shares having risen substantially through 2026. The earnings beat on both the top and bottom lines reflected the lumpy but lucrative nature of milestone-based revenue, and the market's focus turned to management commentary on the call regarding the early launch trajectory of MIMRYLO and the timing of the PN-881 Phase 2b trial. Investors interpreted the results as validation of the company's partnership model, while also watching closely whether rising R&D investment signals disciplined reinvestment in the internal pipeline rather than margin erosion.

Forward Outlook and Key Factors to Monitor

Following this milestone-heavy quarter, several factors will shape how investors evaluate Protagonist Therapeutics going forward.

First, the commercial launches of MIMRYLO and ICOTYDE remain the most visible near-term drivers. Prescription trends, physician adoption, and royalty recognition from Takeda and Johnson & Johnson will be key indicators of whether recurring revenue can begin to complement the milestone windfalls.

Second, the company has signaled a deliberate step-up in R&D spending, largely tied to advancing PN-881, its oral IL-17 (interleukin-17) antagonist, into a comprehensive Phase 2 psoriasis program. Trial initiation timing, enrollment progress, and any early data readouts will be important catalysts for the pipeline narrative.

Finally, investors will monitor the balance sheet and cost trajectory. With $834.6 million in cash and marketable securities, the company has substantial runway, but rising clinical manufacturing and CMC (chemistry, manufacturing, and controls) expenditures, headcount growth, and stock-based compensation could pressure operating margins. How management balances investment with profitability will be a central theme in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations